InnoCare Pharma Limited (9969.HK)
HKD 10.44
(2.76%)
HKD 10.44
(2.76%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.34 Billion CNY | 7.71% |
| 2022 | 1.25 Billion CNY | -1.23% |
| 2021 | 1.26 Billion CNY | 8.08% |
| 2020 | 1.17 Billion CNY | 3.32% |
| 2019 | 1.13 Billion CNY | 10.31% |
| 2018 | 1.02 Billion CNY | 654.81% |
| 2017 | 136.41 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 1.38 Billion CNY | 1917.99% |
| 2024 Q1 | 68.76 Million CNY | -94.9% |
| 2023 Q1 | 321.79 Million CNY | -74.31% |
| 2023 FY | 1.34 Billion CNY | 7.71% |
| 2023 Q3 | 53.29 Million CNY | -95.86% |
| 2023 Q2 | 1.28 Billion CNY | 300.31% |
| 2023 Q4 | 1.34 Billion CNY | 2431.75% |
| 2022 Q4 | 1.25 Billion CNY | 290.05% |
| 2022 Q3 | 321.16 Million CNY | -74.86% |
| 2022 Q2 | 1.27 Billion CNY | 0.0% |
| 2022 Q1 | - CNY | -100.0% |
| 2022 FY | 1.25 Billion CNY | -1.23% |
| 2021 Q4 | 1.26 Billion CNY | 0.0% |
| 2021 FY | 1.26 Billion CNY | 8.08% |
| 2021 Q1 | 1.22 Billion CNY | 4.68% |
| 2021 Q2 | 1.24 Billion CNY | 1.62% |
| 2020 Q4 | 1.17 Billion CNY | 0.59% |
| 2020 Q2 | 1.15 Billion CNY | 0.48% |
| 2020 Q1 | 1.15 Billion CNY | 1.29% |
| 2020 FY | 1.17 Billion CNY | 3.32% |
| 2020 Q3 | 1.16 Billion CNY | 0.92% |
| 2019 Q1 | 3.58 Billion CNY | 247.81% |
| 2019 FY | 1.13 Billion CNY | 10.31% |
| 2019 Q3 | 1.02 Billion CNY | -71.48% |
| 2019 Q2 | 3.58 Billion CNY | 0.0% |
| 2019 Q4 | 1.13 Billion CNY | 11.21% |
| 2018 FY | 1.02 Billion CNY | 654.81% |
| 2018 Q4 | 1.02 Billion CNY | 0.0% |
| 2017 FY | 136.41 Million CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 52.86 Million HKD | -2452.275% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.93 Billion HKD | 77.25% |